港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

瑞博生物-B

55.050

+0.1500.27%

成交量：5.98万

成交额：330.82万

市值：93.89亿

市盈率：-23.15

高：56.850

开：54.900

低：53.850

收：54.900

52周最高：95.800

52周最低：51.200

股本：1.71亿

香港流通股本：1.71亿

量比：0.34

换手率：0.04%

股息：- -

股息率：- -

每股收益(LYR):-2.378

净资产收益率：--

总资产收益率：--

市净率：-141.92

市盈率(LYR):-23.15

市销率: 46.03

数据加载中...

总览公司新闻资讯公告

瑞博生物－Ｂ(06938)出现大手卖出9.86万股，成交价$53.45，涉资527.017万

阿斯达克财经

瑞博生物-B(06938.HK)拟3月25日举行董事会会议以审批年度业绩

医药行业月报2026/02：创新药BD超预期，全球化合作推动价值重构

瑞博生物-B（06938）更新2026年2月股份变动月报表，股本增至170,554,910股

《大行》花旗首予瑞博生物(06938.HK)“买入”评级目标价102元

阿斯达克财经

瑞博生物-B03月03日主力净流出70.8万元散户资金买入

GSK乙肝新药叩门上市，小核酸商业化拐点已至

瑞博生物-B启动RBD7022注射液治疗高脂血症III期临床试验

瑞博生物-B(06938)：RBD7022注射液即将于中国启动用于治疗高血脂症适应症的 III期临床试验

LDL-C降低75%！齐鲁制药/瑞博生物降脂siRNA疗法启动III期临床

医药魔方Info

瑞博生物-B02月27日主力净流入2386万元散户资金抛售

中邮证券：siRNA药物机制优势突出递送为核心技术

智通财经网

国泰海通：FXI引领抗凝药产业新变革多技术路线竞逐蓝海

【国联民生医药】医药周报20260223：春节期间医药行业重点事件梳理

医耀科技创新骑手

45天狂揽490亿美元，2026中国创新药BD加速升温

中金：首予瑞博生物-B(06938)“跑赢行业”评级目标价100港元

智通财经网

追求乙肝功能性治愈！国内 7 家企业进展迅速，最快已 III 期

2026年中国生物科技授权交易将迎爆发式增长，有望创历史新高

近 60 亿美元！不到十天两起小核酸授权出海

瑞博生物-B(06938)因悉数行使超额配股权发行474.14万股

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/06938/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":55.05,"timestamp":1774426110799,"preClose":54.9,"halted":0,"volume":59800,"delay":0,"changeRate":0.002732240437158444,"floatShares":170554910,"shares":170554910,"eps":-2.377997514562271,"marketStatus":"已收盘","change":0.15,"latestTime":"03-25 16:08:30","open":54.9,"high":56.85,"low":53.85,"amount":3308150,"amplitude":0.054645,"askPrice":55.7,"askSize":400,"bidPrice":55,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-1.6066778082705884,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":54.9,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":0.335804,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"--","roe":"--","lyrEps":-2.377998,"volumeRatio":0.335804,"shares":170554910,"dividePrice":0,"high":56.85,"amplitude":0.054645,"preClose":54.9,"low":53.85,"week52Low":51.2,"pbRate":"-141.92","psRate":"46.03","week52High":95.8,"institutionHeld":0,"latestPrice":55.05,"committee":0.666667,"eps":-2.377997514562271,"divideRate":0,"volume":59800,"delay":0,"ttmEps":-1.6066778082705884,"open":54.9,"prevYearClose":57.97,"prevWeekClose":57.05,"prevMonthClose":68.5,"prevQuarterClose":57.97,"fiveDayClose":60,"twentyDayClose":71.5,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774402200000,"name":null,"time":"","dateTimestamp":1774368000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1773417600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-03-24","current":-34.263248,"percent":0.96,"low":-50.513246,"twenty":-48.535001,"median":-40.617956,"eighty":-38.832211,"high":-35.975036,"avg":-42.645244,"sd":4.489462,"marketCap":9363464559},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-24","current":-37.354591,"twenty":-48.535001,"median":-40.617956,"eighty":-38.832211,"marketCap":9363464559}],"updateTime":1774448270123},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621725501","title":"瑞博生物－Ｂ(06938)出现大手卖出9.86万股，成交价$53.45，涉资527.017万","url":"https://stock-news.laohu8.com/highlight/detail?id=2621725501","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621725501?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 10:25","pubTimestamp":1774232700,"startTime":"0","endTime":"0","summary":"[大手成交]瑞博生物－Ｂ(06938)在上午10:25出现大手卖出，成交量为9.86万，成交价为港币$53.45，涉资527.017万。至目前为止，股价跌4.382%，今日最高价为$56.0，而最低价为$53.25，总成交量为15.12万股，总成交金额港币$810.986万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603235628/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603235628/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2618138477","title":"瑞博生物-B(06938.HK)拟3月25日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138477","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138477?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 18:07","pubTimestamp":1773310024,"startTime":"0","endTime":"0","summary":"格隆汇3月12日丨瑞博生物-B(06938.HK)公告，董事会会议将于2026年3月25日(星期三)举行，藉以(其中包括)考虑及批准集团截至2025年12月31日止年度业绩及其发布，并考虑建议派发末期股息(如有)及处理其他事务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260312/32063755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2618699505","title":"医药行业月报2026/02：创新药BD超预期，全球化合作推动价值重构","url":"https://stock-news.laohu8.com/highlight/detail?id=2618699505","media":"中国银河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618699505?lang=zh_cn&edition=fundamental","pubTime":"2026-03-08 12:07","pubTimestamp":1772942852,"startTime":"0","endTime":"0","summary":"核心观点2026开年BD超预期，重磅交易密集落地。交易金额持续提升标志着中国创新资产价值的全球合作信任体系正逐渐建立。合作新范式推动中国创新药价值重构。预计未来更多中国创新药企业达成平台级战略合作，与跨国MNC深度绑定并快速接入全球体系，实现全球利益最大化，推动估值体系重构。医药行业表现弱于沪深300。截至2026年2月28日，医药行业一年滚动市盈率为37.20倍，沪深300为14.12倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603081207369545173f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603081207369545173f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938","06978","BK1574"],"gpt_icon":0},{"id":"1113065955","title":"瑞博生物-B（06938）更新2026年2月股份变动月报表，股本增至170,554,910股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113065955","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113065955?lang=zh_cn&edition=fundamental","pubTime":"2026-03-05 17:40","pubTimestamp":1772703632,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年3月5日披露2026年2月股份变动月报。报告期为2026年2月1日至2026年2月28日。根据公告披露，已发行股份自上月底的165,813,510股增加4,741,400股至170,554,910股，法定/注册股本由人民币165,813,510元增至人民币170,554,910元。报告显示，现有2,113,987份尚未行使的期权，行使价为每股人民币3.70元，截至2028年1月9日方可开始行使。截至2026年2月28日，公司总股本数量变动后为170,554,910股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2617990575","title":"《大行》花旗首予瑞博生物(06938.HK)“买入”评级  目标价102元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617990575","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617990575?lang=zh_cn&edition=fundamental","pubTime":"2026-03-05 10:37","pubTimestamp":1772678220,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，瑞博生物-B(06938.HK) 是siRNA领域的龙头企业，拥有具差异化药物管线、领先的药物递送技术平台等核心优势。该行认为，瑞博生物的核心候选药物RBD4059，有望成为治疗血栓性疾病的突破性药物，该药销售潜力可达超过60亿美元，而该潜力被市场低估。该行首予公司“买入(高风险)”评级，目标价102元。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260127111330476_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260127111330476_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1506799/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1506799/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06938"],"gpt_icon":0},{"id":"2616043374","title":"瑞博生物-B03月03日主力净流出70.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616043374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616043374?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 16:15","pubTimestamp":1772525757,"startTime":"0","endTime":"0","summary":"03月03日, 瑞博生物-B股价跌5.06%，报收61.00元，成交金额1771.5万元，换手率0.17%，振幅9.26%，量比1.30。瑞博生物-B今日主力资金净流出70.8万元，上一交易日主力净流入1308.1万元。该股近5个交易日下跌14.69%，主力资金累计净流入3623.3万元；近20日主力资金累计净流入3419.2万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2616188413","title":"GSK乙肝新药叩门上市，小核酸商业化拐点已至","url":"https://stock-news.laohu8.com/highlight/detail?id=2616188413","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616188413?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 19:05","pubTimestamp":1772449503,"startTime":"0","endTime":"0","summary":"截至目前，Alnylam已形成7款商业化产品梯队。英克司兰钠是全球首个siRNA降脂药，也是首款面向常见慢性病的小核酸药物，它的成功具有里程碑意义。这些技术创新，共同驱动小核酸药物治疗潜力不断释放，推动市场进入加速增长通道。2月23日，前沿生物与GSK达成独家授权协议，GSK获得两款siRNA管线全球开发、生产及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030220293595429ddf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030220293595429ddf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1165985607","title":"瑞博生物-B启动RBD7022注射液治疗高脂血症III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165985607","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165985607?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 08:11","pubTimestamp":1772410268,"startTime":"0","endTime":"0","summary":"瑞博生物-B（股票代码：06938）近日宣布，其研发的RBD7022注射液将在中国正式启动针对高脂血症治疗的III期临床试验。该试验旨在进一步评估该药物在更广泛患者群体中的安全性与有效性，标志着其在心血管代谢疾病治疗领域的研发进程迈入关键阶段。高脂血症作为常见的心血管风险因素，其创新疗法的推进备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2616877702","title":"瑞博生物-B(06938)：RBD7022注射液即将于中国启动用于治疗高血脂症适应症的 III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877702","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616877702?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 08:11","pubTimestamp":1772410260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)公布，集团自主研发的RBD7022注射液已由合作方齐鲁制药有限公司(齐鲁制药)完成III期临床试验登记公示，即将启动III期临床试验。RBD7022注射液是一款靶向PCSK9的siRNA药物。PCSK9是一种酶，在调节体内胆固醇，尤其是通常被称为“LDL-C”或“坏胆固醇”的低密度脂蛋白(LDL)胆固醇的水平方面起关键作用，可作为管理高胆固醇血症的一种治疗选择，旨在降低与高胆固醇水平相关的心血管疾病风险。2023年12月，公司将RBD7022注射液在中国内地、中国香港和中国澳门开发、生产和商业化的独家权利授予齐鲁制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK1161","06938"],"gpt_icon":0},{"id":"2614815508","title":"LDL-C降低75%！齐鲁制药/瑞博生物降脂siRNA疗法启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2614815508","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614815508?lang=zh_cn&edition=fundamental","pubTime":"2026-02-28 14:20","pubTimestamp":1772259649,"startTime":"0","endTime":"0","summary":"2月27日，美国临床试验收录网站显示，齐鲁制药引进的小核酸新药QLC7401启动了首个III期临床试验，旨在评估该药物联合降脂药物治疗伴低密度脂蛋白胆固醇升高的原发性高胆固醇血症或混合性高脂血症的有效性和安全性。RBD7022是瑞博生物基于其自主创新的RIBO-GalSTAR肝靶向递送技术开发的GalNAc缀合siRNA药物，旨在通过靶向PCSK9治疗高血脂症。在I期研究中，接受或未接受他汀治疗的高胆固醇血症患者经RBD7022治疗后，LDL-C最大降幅均可达75%，并在6个月随访时仍然维持效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602281424059542587c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602281424059542587c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01093","BK1191","01477","06938","BK1574"],"gpt_icon":0},{"id":"2614869918","title":"瑞博生物-B02月27日主力净流入2386万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614869918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614869918?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 16:15","pubTimestamp":1772180151,"startTime":"0","endTime":"0","summary":"02月27日, 瑞博生物-B股价涨1.93%，报收68.50元，成交金额2687.6万元，换手率0.23%，振幅2.98%，量比3.18。瑞博生物-B今日主力资金净流入2386万元，上一交易日主力净流出0万元。该股近5个交易日下跌5.45%，主力资金累计净流入2386万元；近20日主力资金累计净流入1868.0万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2614699958","title":"中邮证券：siRNA药物机制优势突出 递送为核心技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2614699958","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614699958?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 11:04","pubTimestamp":1772161440,"startTime":"0","endTime":"0","summary":"中邮证券发布研报称，siRNA药物可精准沉默致病蛋白，优势显著，递送系统为核心技术。海外巨头基于GalNAc肝递送平台，针对心血管靶点的药物已进入收获期。中邮证券主要观点如下：siRNA药物机制优势突出，递送为核心技术相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成为新药开发热门方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938","01276"],"gpt_icon":0},{"id":"2614772030","title":"国泰海通：FXI引领抗凝药产业新变革 多技术路线竞逐蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2614772030","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614772030?lang=zh_cn&edition=fundamental","pubTime":"2026-02-25 13:37","pubTimestamp":1771997868,"startTime":"0","endTime":"0","summary":"FXI开启抗凝新时代，多技术路线竞逐蓝海研究表明，凝血因子XI是推动病理性血栓的重要因子，但在大多数情况下对正常止血并非必需，比如具有遗传性FXI缺乏的人群，血栓事件的发生率明显降低，而自发性出血的风险并未显著增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","01276","BK0276","06938","BK0028","BK1161","BK0012","LU1023057109.AUD","LU0359201612.USD","BK0188","BK0184","LU0359201885.HKD","LU2543165471.USD","BK0183","BK0201","BK1147","601211","BK1564","02611","BK1191"],"gpt_icon":0},{"id":"2613204910","title":"【国联民生医药】医药周报20260223：春节期间医药行业重点事件梳理","url":"https://stock-news.laohu8.com/highlight/detail?id=2613204910","media":"医耀科技创新骑手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613204910?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 14:18","pubTimestamp":1771827529,"startTime":"0","endTime":"0","summary":"1春节期间医药行业重点事件梳理1.1创新药BD交易实现开门红，优势产品海外研发和注册进展顺利2026年春节前后，中国创新药对外BD交易实现开门红，全年交易金额有望再攀新高。根据医药魔方，截至2026年2月15日，中国创新药2026年对外BD交易首付款规模超过2025年任一季度，总金额超过2025年全年水平的1/3。3）2月17日，石药集团发布公告，SYH2082的临床试验申请获得FDA批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223142808a71517c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223142808a71517c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161","02228","BK1515","BK1564","02268","01801","02155","02359","02252","09606","01456","03759","09939","09995","BK1147","BK1574","01530"],"gpt_icon":0},{"id":"2613405217","title":"45天狂揽490亿美元，2026中国创新药BD加速升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2613405217","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613405217?lang=zh_cn&edition=fundamental","pubTime":"2026-02-21 10:31","pubTimestamp":1771641097,"startTime":"0","endTime":"0","summary":"2026年开年，中国创新药对外BD交易势头不减，再攀新高。这意味着，开年45天，中国创新药对外BD交易首付款规模已超过2025年任一季度，总金额更已超过2025年全年水平的1/3。而对于这8个极早期项目，阿斯利康开出了12亿美元首付款、185亿美元总金额的高价，也让这笔交易成为中国创新药BD历史上总金额最大的交易。勃林格殷格翰则以4,200万欧元、10.16亿欧元里程碑付款获得了先声药业TL1A/IL-23p19双抗SIM0709的大中华区外全球权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221104715a4b8203c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221104715a4b8203c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1951186391.HKD","06978","LU1226287792.SGD","02096","LU0314109678.HKD","LU2039709279.SGD","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0067412154.USD","IE00B5MMRT66.SGD","BK1574","LU0072913022.USD","LU1993786604.SGD","LU1807302812.USD","IE0008369823.USD","BK1515","LU1226287529.USD","LU1226288170.HKD","SG9999004220.SGD","LU1152091168.USD","LU0315179316.USD","06938","IE0008368742.USD","IE00BZ08YT58.USD","LU0326950275.SGD","BK1161","IE00B031HY20.USD","01093","LU0140636845.USD","LU0880133367.SGD","LU0501845795.SGD","LU1813983027.USD","LU1226288253.USD","01801","BK1191","HK0000165453.HKD","IE00B543WZ88.USD","LU1226287875.USD","BK1521","LU1960683339.HKD","LU1328277881.USD","LU1008478684.HKD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2612230236","title":"中金：首予瑞博生物-B(06938)“跑赢行业”评级 目标价100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612230236","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612230236?lang=zh_cn&edition=fundamental","pubTime":"2026-02-20 09:58","pubTimestamp":1771552683,"startTime":"0","endTime":"0","summary":"截至25年底，公司已拥有7款进入临床阶段的siRNA管线，其中4款处于II期，RBD4059(FXI)、RBD5044(ApoC3)、RBD1016(HBV)是核心资产。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06938"],"gpt_icon":1},{"id":"2611140454","title":"追求乙肝功能性治愈 ！国内 7 家企业进展迅速，最快已 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2611140454","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611140454?lang=zh_cn&edition=fundamental","pubTime":"2026-02-15 07:20","pubTimestamp":1771111229,"startTime":"0","endTime":"0","summary":"当下，追求功能性治愈已成为全球慢性乙肝治疗领域的核心趋势，国内创新药企也紧跟这一方向积极布局，以 ASO 和 siRNA 为主，还包含了细胞疗法、治疗性疫苗等。同月，AHB-137 的 III 期 AUSHINE 临床研究已顺利完成患者入组。2025 年 9 月，该产品被 CDE 纳入拟突破性治疗品种公示名单。另外，腾盛博药将在 2026 年公布两项额外的 IIb 期研究数据。2025 年 9 月，BW-20507 已经完成 II 期临床试验首例患者给药。其 II 期临床试验已经获得批准。目前，正大天晴正在开展 TQA3038 的 Ib/IIa 期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260215073412a4a5af8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260215073412a4a5af8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02137","01611","BK1167","BK1612","06938"],"gpt_icon":0},{"id":"2611165746","title":"2026年中国生物科技授权交易将迎爆发式增长，有望创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165746","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611165746?lang=zh_cn&edition=fundamental","pubTime":"2026-02-13 17:05","pubTimestamp":1770973500,"startTime":"0","endTime":"0","summary":"全球制药企业在专利到期前纷纷削减成本，正加大力度寻找中国研发的创新候选药物，行业分析师预计，今年相关授权交易规模将飙升至历史新高。2026 年至今已宣布38 笔对外授权交易；2025 年全年为186 笔。行业咨询机构 Vision Lifesciences 在 2026 年生物科技授权展望中称，中国在抗体药物偶联物领域全球领先，相关授权交易占全球近90%。首付款大幅上涨随着交易规模扩大，全球药企获取中国药物开发权所需支付的首付款也大幅飙升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","01093","BK1161"],"gpt_icon":0},{"id":"2611165798","title":"近 60 亿美元！不到十天两起小核酸授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165798","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611165798?lang=zh_cn&edition=fundamental","pubTime":"2026-02-13 07:20","pubTimestamp":1770938451,"startTime":"0","endTime":"0","summary":"根据协议条款，瑞博生物将授予 Madrigal 多款 MASH 领域单靶点及双靶点临床前 siRNA 资产的全球独家研发、生产与商业化权利。Madrigal 的 THR-β 激动剂已经获批上市，用于治疗 MASH，2025 年前三季度销售额 6.4 亿美元，预计全年超过 10 亿美元。这是瑞博生物肝靶向 RiboGalSTAR 平台第二次达成重磅出海合作。早在 2023 年，瑞博生物就此平台与勃林格殷格翰达成共同开发治疗 MASH 的小核酸创新疗法的合作，合作总额超 20 亿美元，成为国内首个向 MNC 许可的 RNAi 技术平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2610915655","title":"瑞博生物-B(06938)因悉数行使超额配股权发行474.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610915655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610915655?lang=zh_cn&edition=fundamental","pubTime":"2026-02-12 14:11","pubTimestamp":1770876660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月10日根据悉数行使超额配股权而发行及配发474.14万股H股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":94,"code":"91000000","status":"200"}]}}